An observational study of 11,854 US adults followed for a median of 13.8 years linked higher scores to 29 percent lower all-cause mortality.An observational study of 11,854 US adults followed for a median of 13.8 years linked higher scores to 29 percent lower all-cause mortality.
Death hazard ratios—comparisons of death rates over time—were 2.29 for erythritol and 1.99 for xylitol, comparing highest versus lowest blood-level quarters.Death hazard ratios—comparisons of death rates over time—were 2.29 for erythritol and 1.99 for xylitol, comparing highest versus lowest blood-level quarters.
Among people with diseased upper heart chambers, each 10-minute moderate-to-vigorous activity increase was linked to an estimated 2.78 fewer cases per 1,000 person-years.Among people with diseased upper heart chambers, each 10-minute moderate-to-vigorous activity increase was linked to an estimated 2.78 fewer cases per 1,000 person-years.
In UK Biobank, the model outperformed three established clinical risk scores, with 6.9% to 22.5% relative improvements in risk-ranking performance.In UK Biobank, the model outperformed three established clinical risk scores, with 6.9% to 22.5% relative improvements in risk-ranking performance.
Over a median 2.9 years, 76,412 people with atrial fibrillation died, compared with 34,555 matched controls without it in an English health-record study.Over a median 2.9 years, 76,412 people with atrial fibrillation died, compared with 34,555 matched controls without it in an English health-record study.
One-year mortality reached 9.3% in patients with three or more social disadvantage markers, versus 3.6%, 6.3%, and 6.1% in those with zero, one, and two.One-year mortality reached 9.3% in patients with three or more social disadvantage markers, versus 3.6%, 6.3%, and 6.1% in those with zero, one, and two.
In an observational study of 2,594 heart failure patients followed for three years, blood tests measuring biological age improved death risk prediction beyond clinical…In an observational study of 2,594 heart failure patients followed for three years, blood tests measuring biological age improved death risk prediction beyond clinical tools.
